A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study

Authors:

Abstract
No abstract available
Funding Information
  • Sanofi
  • Roche
  • Bristol-Myers Squibb
  • Celgene
  • Amgen
  • Novartis
  • AstraZeneca
  • Merck

This publication has 14 references indexed in Scilit: